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Interferon-alpha treatment rapidly 
clears Hepatitis E virus infection in 
humanized mice
Martijn D. B. van de Garde1, Suzan D. Pas2, Gertine W. van Oord1, Lucio Gama4,  
Youkyung Choi5, Robert A. de Man1, Andre Boonstra1 & Thomas Vanwolleghem  1,3
Antiviral treatment options for chronic Hepatitis E Virus (HEV) infections are limited and immunological 
determinants of viral persistence remain largely unexplored. We studied the antiviral potency of 
pegylated interferon-α (pegIFNα) against HEV infections in humanized mice and modelled intrahepatic 
interferon stimulated gene (ISG) responses. Human gene expression levels in humanized mouse 
livers were analyzed by qPCR and Nanostring. Human CXCL10 was measured in mouse serum. HEV 
genotype 3 (gt3) infections were cleared from liver and feces within 8 pegIFNα doses in all mice and 
relapsed after a single pegIFNα injection in only half of treated animals. Rapid viral clearance by 
pegIFNα was confirmed in HEV gt1, but not in Hepatitis B Virus infected animals. No ISG induction was 
observed in untreated HEV gt3 and gt1 infected humanized livers compared to control chimeric mice, 
irrespective of the human hepatocyte donor, viral isolate or HEV infection duration. Human specific 
ISG transcript levels in mouse liver increased significantly after pegIFNα treatment and induced high 
circulating human CXCL10 in mouse serum. In conclusion, HEV gt1 and gt3 infections do not elicit 
innate intrahepatic immune responses and remain highly sensitive to pegIFNα in immunocompromised 
humanized mice.
Hepatitis E Virus (HEV) infections are emerging in western countries1. HEV is a non-enveloped positive-sense 
single-stranded RNA virus, belonging to the family Hepeviridae within the genus Orthohepevirus2. Transmission 
mainly occurs through the fecal-oral route via contaminated water in developing countries or through the con-
sumption of undercooked meat in industrialized countries3. Seven different genotypes have been described so far, 
of which genotype (gt) 1 and 3 are most prevalent in humans2. In healthy individuals, HEV mostly resolves spon-
taneously without severe symptoms, but pregnant women seem to be at risk of developing fulminant liver failure 
by HEV gt1 with mortality rates up to 25%4, 5. On the other hand, increasing rates of chronic gt3 infections have 
been described in immunocompromised patients in Europe, resulting in progressive liver fibrosis and cirrhosis6–8. 
These data indicate that host pathogen interactions differ between both genotypes.
Antiviral treatment options for chronic HEV infected immunocompromised patients are limited. Ribavirin 
(RBV) leads to sustained viral responses in roughly 75% of patients, but is hampered by RBV-induced anemia 
and the need for recombinant erythropoietin injections or transfusions in more than half of patients9, 10. As an 
alternative, pegylated interferon-alpha (pegIFNα) has been administered to a few patients in doses comparable to 
Hepatitis C virus (HCV) treatment regimens10, 11. However, factors associated with interferon (IFN)-susceptibility, 
the optimal pegIFNα dose or treatment duration have not been investigated in vivo.
The anti-HEV effects of IFNα in vitro differ according to the target cell and viral strain used. In vitro HEV 
models consist of human hepatoma and lung adenocarcinoma cell-lines, in which replication of subgenomic or 
full length replicons and seldom intact patient-derived viruses are studied12–16. Patient-derived HEV gt3 cultures 
show slow viral propagation, whereas HEV gt1 can only be cultured in vitro after induction of endoplasmic retic-
ulum stress in the host cell line15–17. While HEV gt1 replication has been shown to be adequately suppressed by 
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exogenous IFNα, HEV gt3 replication has not18–20. In addition, viral inhibition of the interferon stimulated gene 
(ISG) responses have been described as a determining factor for IFNα susceptibility in vitro21. As the studied host 
cells are either no target cells in vivo (A549 cells) or are hampered by defects in their innate immune signaling 
(Huh7 and Huh7.5), the host response towards genuine patient-derived HEV in differentiated human hepato-
cytes remains to be established18, 22. In addition, several clinical observations are not matched by in vitro viral 
replication data. HEV containing an in vivo RBV acquired mutation (K1383N), showed conflicting results in vitro 
with decreased viral replication and increased RBV-sensitivity23. Furthermore, the antiviral efficacy of sofosbuvir 
against HEV showed discrepancies in different in vitro and in vivo studies24–27.
Recently, we and others have shown that human-liver chimeric mice can be used to study HEV infection in 
differentiated human hepatocytes in vivo15, 28, 29. Here, we examined baseline ISG expression levels and suscep-
tibility to pegIFNα in HEV gt1 and gt3 infected humanized mice. We demonstrate that HEV gt1 infections lead 
to higher virus loads in mouse feces, bile and liver compared to HEV gt3 infections, without the induction of 
intrahepatic human innate immune responses. Both HEV genotypes, but not Hepatitis B virus (HBV), are cleared 
after a few doses of pegIFNα in vivo, an effect accompanied by a clear increase of human ISG transcript levels in 
liver and of circulating human CXCL10 levels in mouse serum.
Results
Higher viral burden in HEV gt1 compared to gt3 infected human-liver chimeric mice. Humanized 
UPA+/+NOG mice were i.v. inoculated with a filtered feces suspension containing either HEV gt3 or HEV gt1 
and were observed for 2, 6 or 14 weeks until euthanization. Infected mice were housed individually to prevent 
inter-mice contamination. During the infection course a higher percentage of HEV gt1 infected mice presented 
viremia, but the peak viral load in serum was similar to HEV gt3 infected mice (2.6 ± 0.4 and 1.4 ± 0.4 log HEV 
RNA IU/ml, respectively, Fig. 1a). The peak HEV RNA load in feces was significantly higher in HEV gt1, com-
pared to HEV gt3 infected mice (5.9 ± 0.2 and 4.2 ± 0.5 log HEV RNA IU/gram, respectively, P = 0.029; Fig. 1b). 
HEV gt1 infected mice also had higher viral loads in bile (6.1 ± 0.2 vs. 5.2 ± 0.4 log HEV RNA IU/ml, respectively, 
P = 0.038; Fig. 1c) and liver (6.8 ± 0.2 vs 5.8 ± 0.3 log HEV RNA IU/gram, respectively, P = 0.015; Fig. 1d) at 
euthanasia, despite similar levels of serum human albumin compared to HEV gt3 infected mice, indicative for 
similar degrees of human chimerism (1.6 ± 0.4 and 1.9 ± 0.5 mg/ml, respectively, Fig. 1e). Despite lower absolute 
HEV gt1 inocula compared to HEV gt3, animals challenged with undiluted feces suspensions demonstrated 
similar results reaching higher HEV gt1 RNA levels in bile (P = 0.038), liver (P = 0.006), and feces (P = 0.06) 
compared to HEV gt3 RNA levels. These results point to a higher in vivo virulence of HEV genotype 1 compared 
genotype 3.
No induction of intrahepatic innate immune responses in HEV gt1 or gt3 infected human-liver 
chimeric mice. Because of the HEV gt1 and gt3 clinical differences4, 6–8 and different viral burdens in human-
ized mice, we examined the human host response in chimeric livers 2, 6, or 14 weeks after infection with either 
HEV gt1 or gt3. Using qRT-PCR we could not detect a significant increase in transcript levels of alpha or beta 
IFNs (data not shown), pathogen recognition receptors TLR3 and DDX58 (Fig. 2a), transcription factor STAT1 
(Fig. 2b), or ISGs CXCL9, CXCL10, ISG15, RSAD2, OAS1, MX1, and IFIT1 (Fig. 2c). Furthermore, longer dura-
tion of HEV gt3, but not HEV gt1 infection led to significantly decreased STAT1, RSAD2 and MX1 expression 
levels in the liver (Fig. 2b+c). None of these human transcripts were detected in non-chimeric mouse livers.
In order to evaluate a broader number of genes, Nanostring analysis of 594 human specific immunology-related 
genes was performed on chimeric (serum hAlb 2.5 ± 0.8 mg/ml) gt3 HEV-infected livers (6.1 ± 0.25 log HEV 
RNA IU/gr) at different time points post infection. Human transcript specificity was confirmed by including 
RNA from 3 non-chimeric livers and led to the removal of 50 cross-reactive genes from further analyses. Based 
on set criteria (<100 relative RNA counts and below four times the standard deviation in all samples), 255 genes 
were defined as non-expressed. Principal component analyses did not reveal clustering of samples (Fig. 2d). 
Of 18 genes related to interferon signaling and response, none showed consistent upregulation compared to 
Figure 1. Higher viral loads in HEV gt1 compared to HEV gt3 infected mice despite similar degrees of human 
chimerism. Comparison of peak HEV RNA levels as measured by qRT-PCR in serum (a) and in feces (b). At 
sacrifice viral titers of HEV gt3 and gt1 infected mice were compared in bile (c, n = 7 and n = 6, respectively) 
and in liver (d). Human albumin levels were determined in mouse serum to quantify degree of chimerism at 
euthanasia (e). *P < 0.05, n = 20 for HEV gt3 and n = 10 for HEV gt1 (a,b,d,e). Data are pooled from 2, 6, and 
14 weeks infection experiments. Red dots indicate mice who received a diluted HEV inoculum (a–d).
www.nature.com/scientificreports/
3Scientific RepoRts | 7: 8267  | DOI:10.1038/s41598-017-07434-y
non-infected chimeric mice (Fig. 2e). Down regulation of STAT1 and MX1 as observed by qRT-PCR, was con-
firmed in the Nanostring gene expression data (Fig. 2b+c,e). Taken together, these data show that ongoing HEV 
gt1 or gt3 replication for up to 14 weeks does not elicit an innate immune response in human hepatocytes in vivo.
Figure 2. Minimal intrahepatic interferon-stimulated gene induction in HEV infected human-liver chimeric 
mice, between weeks 2 to 14 post infection. Whole chimeric-liver RNA was isolated from HEV gt3 and gt1 
infected mice and analyzed for the human specific gene expression of sensing molecules TLR3 and DDX58 (a), 
transcription factor STAT1 (b), and interferon stimulated genes CXCL9, CXCL10, ISG15, RSAD2, OAS1, MX1 
and IFIT1 (c) using qRT-PCR. Groups consist of n = 4, 6, 4, 3, 6 and 4 mice from left to right (a–c). Given values 
on y-axes are fold changes over HEV RNA negative chimeric-livers transplanted with the same hepatocyte 
donor. X-axes shows weeks post infection, HEV genotype, and hepatocyte donor. Significance was assessed 
within groups of the same hepatocyte donor using Krukskal-Wallis one-way Anova with Dunnett’s Multiple 
comparison test. *P < 0.05, Gray bars indicate HEV gt1, black bars HEV gt3 (a–c). In-depth human gene 
expression analysis was performed on RNA from chimeric mouse livers before infection, and after 2, 6 and 14 
weeks of HEV gt3 infection using nCounter® Human Immunology V2 panel. Principal component 1 (x-axis) 
and 2 (y-axis) comprise 49% of the variance between samples using all non-cross reactive genes (d). Uninfected 
samples are indicated in green, infected samples are indicated in blue, red (HEV0069), purple (HEV0122) and 
yellow and by the number of weeks infected HEV2, HEV6, HEV6, HEV14, respectively (d). Heatmap shows 
fold change over average of 4 uninfected mice for interferon signaling and response genes (e). Gene legend is 
indicated on the right side and sample legend below the heatmap (e). Dark red indicates ≥ 5 fold change, and 
dark blue ≤ 5 fold change (e).
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HEV but not HBV is sensitive to pegIFNα-2a treatment in human-liver chimeric mice. Baseline 
ISG expression in hepatocytes has been shown to predict the response to IFNα treatment in chronic HCV 
infected patients30–32. As HEV did not induce an ISG response in vivo, we examined the HEV-sensitivity to 
pegIFNα treatment. As a negative antiviral control, we applied the same treatment to HBV gtA infected mice, 
which has been shown to only slightly reduce serum HBV DNA levels in a similar humanized mouse model33. 
After 1 to 2 pegIFNα injections, HEV gt3 RNA became undetectable in feces of all treated animals (Fig. 3a–c). 
Complete viral clearance in liver and bile was observed in all mice at euthanasia 24 hours after 4 or 8 pegIFNα 
injections (Fig. 3d). To examine whether a single dose of 30 µg/kg pegIFNα would suffice to clear HEV gt3 in 
vivo, 4 animals received one injection after 6 weeks of ongoing HEV gt3 replication and were observed for an 
additional 4 weeks. This led to a complete viral clearance in 2 out of 4 mice and relapse in feces in the remainder 2 
(Fig. 3c+d). Four weeks after the initial single pegIFNα dose, the latter 2 animals received repetitive 10-fold lower 
pegIFNα doses for 2 weeks. Again a steep decline in fecal HEV RNA loads was noted, but HEV RNA reemerged 
in feces and was detectable in bile and liver at euthanasia one day after the second pegIFNα treatment course 
(Fig. 3c+d). The high in vivo HEV IFNα sensitivity was corroborated in HEV gt1 infected animals. Again rapid 
suppression of HEV replication was noted in feces (Fig. 3e), liver and bile (data not shown) after a 2 week treat-
ment course with 30 µg/kg pegIFNα. In contrast, a similar treatment regimen of HBV gtA infected mice induced 
a maximum decline of 0.7 ± 0.2 log HBV DNA copies/ml in serum with high intrahepatic viral loads at nec-
ropsy (6.9 ± 0.6 log HBV DNA copies/gr liver) (Fig. 3f). Non-treated HEV gt1, HEV gt3 and HBV infected mice 
never showed spontaneous viral clearance (Fig. 1b–d and Suppl. Fig. 2a–c), nor was loss of human chimerism 
in pegIFNα-treated animals observed, based on persistent detection of human albumin levels in mouse serum 
(data not shown). These data indicate that HEV, but not HBV is highly sensitive to pegIFNα in humanized mice.
Figure 3. HEV is more sensitive than HBV to pegIFNα treatment in human-liver chimeric mice. HEV RNA 
was measured by qRT-PCR in feces of human-liver chimeric mice infected with HEV gt3 or HEV gt1 before and 
during 4 weeks (a, n = 3), 2 weeks (b, n = 4; e, n = 3). and single (c, n = 4) pegIFNα treatment. Horizontal gray 
bars indicate pegIFNα treatment duration and dosage in µg/kg (a,b). Arrow indicates time point of the single 
30 µg/kg pegIFNα injection (c). One day after last dosage mice were sacrificed and viral load was determined 
in liver and bile (d). Non-treated infected mice were added as control (d). X-axes indicates number of pegIFNα 
injections (d). HBV DNA was measured in serum of HBV gtA infected human-liver chimeric mice before 
and during pegIFNα treatment, and one day after last treatment mice were euthanized and intrahepatic HBV 
DNA was measured (f, n = 6). #indicates 3 µg/kg pegIFNα dosages. All mice were transplanted with the same 
hepatocyte donor (HD2, a–f). Y-axes indicate log HEV RNA IU/gram (a–c,d left panel, e), log HEV RNA IU/ml 
(d right panel), and log HBV DNA copies/ml (f). X-axes indicate days post infection (a–c,e–f).
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Upregulation of intrahepatic ISG and serum CXCL10 upon pegIFNα treatment. To examine 
whether pegIFNα induced HEV clearance was associated with an induction of human hepatocyte ISG responses, 
human specific transcript levels of several innate immune response genes were studied in chimeric livers of HEV 
gt3, HEV gt1 and HBV gtA infected and pegIFNα treated animals. PegIFNα treatment led to an 20-fold increase 
of CXCL10 transcription, conjointly with induction of TLR3, DDX58, STAT1, CXCL9, ISG15, RSAD2, OAS1, 
MX1, and IFIT1 genes in the livers of HEV infected humanized mice (Fig. 4a and Suppl. Fig. 3). In addition, treat-
ment was associated with an increase in serum human CXCL10 levels of HEV gt1 and gt3 infected mice (59 ± 10 
and 108 ± 14 pg/ml, respectively, Fig. 4b). Interestingly, intrahepatic CXCL10 expression levels remained elevated 
(3.4-fold compared to HEV-infected non-treated mice) 4 weeks after a single pegIFNα dose in the two mice that 
cleared HEV. Similar to previous reports, HBV persistence in vivo was not due to absence of an ISG response, as 
IFIT1, ISG15, MX1, STAT1, and CXCL10 all were strongly induced (Fig. 4a and data not shown)33. Overall, HEV 
but not HBV was found to be sensitive to pegIFNα induced hepatocyte-specific innate responses in vivo.
Discussion
Despite increasing reports on acute and chronic Hepatitis E Virus infections in Europe, antiviral treatment 
options are limited and immunological determinants of viral persistence remain largely unexplored5. Here we 
aimed to study baseline and therapeutically induced innate immune responses in a recently established human-
ized mouse model for chronic HEV infection. We demonstrate that (1) HEV is highly sensitive to pegIFNα 
treatment in vivo; (2) HEV infection in human hepatocytes doesn’t elicit an innate immune response; (3) HEV 
gt1 presents higher viral loads compared to HEV gt3.
HEV gt1 and gt3, but not HBV, showed to be highly sensitive to pegIFNα treatment in immune deficient 
human liver chimeric uPA+/+NOG mice. Viral clearance in feces, liver and bile was achieved after 4 and 2 weeks 
treatment and even after a single pegIFNα injection in 2/4 mice. PegIFNα associated viral clearance was accom-
panied by an increase of intrahepatic human ISGs and serum CXCL10 levels. In line with our data (Fig. 3f), 
the antiviral potency of pegIFNα against other hepatotropic viruses was less pronounced in similar humanized 
mouse models. PegIFNα reduced HBV viremia by 2.5 log IU/ml and HCV loads with 2.3 log IU/ml after 12 and 
4 weeks of treatment respectively, without clearing the infection33–35. Successful IFNα treatment in immunocom-
petent woodchucks chronically infected with woodchuck hepatitis virus (a model for chronic HBV infection), 
is associated with an intrahepatic IFN-γ and NK/T cell gene signature, but not an ISG signature36. All together 
this suggests that pegIFNα has a strong direct anti-viral effect against HEV, whereas HBV and HCV require the 
immune system to achieve viral clearance or complete suppression.
Ongoing HEV gt1 or gt3 replication did not elicit human-innate immune responses in humanized livers of 30 
uPA+/+NOG mice, irrespective of the infection duration, the human hepatocyte donor or viral isolate used. We 
specifically addressed the genomic response of human hepatocytes to HEV without that of infiltrating immune 
cells in our profound immune deficient uPA+/+NOG mice. In addition, we carefully eliminated cross hybridizing 
probes by including non-chimeric mice. After prolonged HEV gt3 infection for more than 3 months, significantly 
lower expression levels of STAT1, RSAD2 and MX1 compared to uninfected controls were observed, suggest-
ing possible viral interference with the host’s cell innate immune signaling. Hepatotropic pathogens have devel-
oped different methods to evade innate immune defenses37. In our model, expression of TLR3 and DDX58 was 
detected in all HEV-infected chimeric livers indicating that these host sensing molecules were not counteracted 
at the transcription level (Fig. 2a). Several studies in HEK293T, A549 and Huh7 cells have suggested that HEV 
can directly interfere with phosphorylation of STAT1 and the induction of IFNα20, 21, 38. However, most of these 
Figure 4. CXCL10 transcripts and protein are induced after pegIFNα treatment in HEV infected mice. RNA 
was isolated from non-treated and 2 weeks pegIFNα treated HEV gt1, gt3 and HBV infected mouse livers and 
was analyzed for the expression of human CXCL10 (a). X-axes indicate treatment dosage and virus genotype (a). 
Given values on y-axes are RNA levels in fold changes over uninfected non-treated mice (a). Human CXCL10 
levels were measured using ELISA in mouse serum of uninfected, HEV-infected and HEV-infected pegIFNα 
treated mice (b). Dotted line indicates lower limit of detection (LLOD) (b). Gray bars indicate HEV gt1, black 
bars HEV gt3 and striped bar uninfected (a + b).
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studies use non-physiological HEV-infection models or are influenced by defects in the innate signaling of target 
cells22. Our findings indicate possible HEV mediated innate immune inhibitory effects in primary human hepat-
ocytes. Further studies in differentiated human hepatocytes are required to determine how HEV is able to prevent 
immune sensing or disrupt innate signaling and how this influences viral fitness.
In contrast to our findings, one recent study infected a similar, but less profound immunodeficient uPA-SCID 
mouse model with the same HEV gt1 strain (Sar-55) and showed elevated ISG expression in 2 HEV-infected mice 
compared to one control animal28. While the impact of the hepatocyte donor type on expression levels cannot be 
disregarded as shown here (Suppl. Fig. 1), remnant mouse natural killer cell and Kupffer cell activity in the SCID 
compared to the NOG background might have contributed to the observed differences39, 40. The role of infiltrat-
ing innate immune cells in the liver during HEV-clearance was recently shown in the chimpanzee model41. In 
HEV-infected chimpanzees the intrahepatic expression levels of BST2 (present in monocytes, macrophages and 
dendritic cells) and not those of the adaptive immune system, corresponded with the expression kinetics of sev-
eral ISG’s, including CXCL10, ISG15 and OAS141, 42.
An important finding of our study was that during both HEV gt1 and gt3 infections, no innate immune 
responses were induced despite higher HEV gt1 viral loads in mouse feces, bile and liver. These observations 
point to an intrinsic phenotypical difference of the distinct HEV genotypes, but cannot explain the different 
immune pathogenesis seen in patients, who have a strikingly different clinical presentation. Not only is disease 
severity higher in HEV gt1 infections, but also chronicity rates for HEV gt1 are found to be low or even zero. 
Possibly, different amounts of viral antigens or epitopes, could induce different magnitudes of natural killer cell 
or HEV-specific T cell responses resulting in respectively more clinical disease or less chronic infections for the 
different genotypes43, 44.
The clinical experience with pegIFN based therapies for chronic HEV is minimal. Eight cases have been 
published of which 5 showed a suppression of viremia at the first measured timepoint after initiation of 
pegIFNα treatment. PegIFNα treatment in HEV infected humanized mice modelled the viral decline seen in 
these 5 patients. It remains however unclear why some chronic HEV patients show slow viral declines upon 
IFN-treatment. We observed a viral relapse in feces, liver and bile of 2 humanized mice after a second pegIFNα 
treatment course (Fig. 3c+d). While animals received a 10-fold lower pegIFNα dose, the relapse might be par-
tially ascribed to elevated intrahepatic ISG levels before retreatment. Increased CXCL10 levels were measured in 
the liver of 2 mice 4 weeks after a single pegIFNα injection, which corresponds to the timepoint at which retreat-
ment was given to the remainder mice of that group. Since in chronic HCV patients the virologic response to 
pegIFNα is associated with low baseline ISG expression levels31, it would be interesting to examine whether this 
holds true for chronic HEV patients as well.
In conclusion, despite higher viral loads for HEV gt1 in human-liver chimeric mice, both HEV gt1 and gt3 do 
not induce an intrahepatic innate immune response. HEV, but not HBV, is highly sensitive to pegIFNα treatment 
in humanized mice.
Material and Methods
Ethics, consent and permissions. The use of patient material was approved by the medical ethical com-
mittees of Erasmus Medical Center and Antwerp University Hospital. Informed consent was obtained from all 
subjects. All animal work was conducted according to relevant Dutch national guidelines. The study protocol was 
approved by the animal ethics committee of the Erasmus Medical Center (DEC nr. 141-12-11).
Mouse origin and genotyping. Urokinase-type plasminogen activator (uPA)/NOD/Shi-scid/IL-2Rγnull 
(NOG) mice were kindly provided by the Central Institute for Experimental Animals (Kawasaki, Japan)45. Mice 
were bred at the Central Animal Facility of the Erasmus Medical Center. Zygosity of mice was determined as 
described previously15. Mice were co-housed with a maximum of 4 mice per individually ventilated cage and were 
fed normal chow ad libitum.
Human hepatocyte transplantation. Six to twelve week old male uPA-homozygous mice were trans-
planted as described previously46. In short, mice were anesthetized and transplanted via intrasplenic injection 
with 0.5 × 106 to 2 × 106 viable commercially available cryopreserved human hepatocytes from 1 of 3 donors 
(Corning, NY, USA; Lonza, Basel, Switzerland; Table 1). Graft take was determined by human albumin in mouse 
serum using an ELISA with human albumin cross-adsorbed antibody (Bethyl laboratories, Montgomery, TX, 
USA) as previously described15.
Viral strains, mouse infection and treatment. HEV gt3 was derived from feces of one of two chronic 
HEV patients (HEV0069 and HEV0122) as described previously15. HEV gt1 Sar-55 was derived from feces of a 
Rhesus macaque that had been originally inoculated with the human Sar-55 strain47. Eight weeks after transplan-
tation human-liver chimeric mice were inoculated intravenously (i.v.) with 200 µl feces suspension containing 
HEV gt3 (8.8 log IU/ml or diluted to 6.8 log IU/ml), HEV gt1 (7.9 log IU/ml or diluted to 6.2 log IU/ml) or 200 µl 
Donor ID Gender Age Race
HD1 Male 2 years Caucasian
HD2 Female 2 years Caucasian
HD3 Female 7 months Caucasian
Table 1. Hepatocyte donors.
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patient serum containing HBV gtA (7.7 log IU/ml). After viral inoculation, mice were housed individually. Mice 
were treated with a single subcutaneous pegIFNα-2a (30 µg/kg unless stated otherwise, Pegasys, Roche, Basal, 
Switzerland) injection or every 3–4 days for 2 or 4 weeks. Overview of viral isolates are shown in Table 2. An 
overview of experimental groups is shown in Table 3 and Suppl. Figure 4.
HEV RNA and HBV DNA detection. The presence of HEV RNA in mouse serum, feces, bile and liver 
was determined by an ISO15189:2012-validated, internally controlled quantitative real-time RT-PCR, described 
previously7, 15. Cycle threshold (Ct) values above 38 were considered background, which corresponds to a lower 
limit of detection of 2.16 log10 HEV RNA units/ml in undiluted human serum. HEV RNAs detected in samples 
with Ct values below 38 are indicated with their calculated values. HBV viral load was measured in mouse serum 
and liver using a dual target approach, using primers and probes targeting preS-gen, as described before48, 49, and 
the X gene (HBV XJfwd12 5′-ggtctgtgccaagtgtttgst-3′, HBV XJprobe 5′-FAM-acgcaacccccactggctggg-BHQ1–3′, 
HBV XJrev12, 5′-tycgcagtatggatcgsc-3′).
RNA isolation of whole liver, generation of cDNA and real-time qPCR. Whole liver RNA was 
isolated using RNeasy mini kit (Qiagen, Hilden, Germany) including DNAse treatment according to manu-
facturer’s protocol starting with homogenization of liver tissue in RLT buffer. cDNA was generated by using 
an iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer’s 
protocol. Human specific gene expression was measured using Taqman primer/probe quantitative PCR, in 
TaqMan® Gene Expression Master Mix (Thermo Fisher Scientific, Waltham, MA, USA). Primer/probe combi-
nations were purchased from Thermo Fisher Scientific; CXCL10 (Hs01124251_g1), CXCL9 (Hs00171065_m1), 
DDX58 (Hs01061436_m1), GAPDH (Hs00266705_g1), IFIT1 (Hs01911452_s1), ISG15 (Hs01921425_s1), 
IFNA1 (Hs00855471_g1), IFNA4 (Hs01681284_sh), IFNB1 (Hs01077958_s1), MX1 (Hs00895608_m1), OAS1 
(Hs00973637_m1), RSAD2 (Hs00369813_m1), STAT1 (Hs01013996_m1), TLR3 (Hs01551078_m1). Expression 
of target genes was normalized to the expression of GAPDH using the formula 2−ΔCt, ΔCt = Cttarget−CtGADPH. 
cDNA from non-chimeric mouse livers was used as control to test cross-reactivity of housekeeping and target 
genes. Due to the difference in hepatocyte donor baseline expression levels of examined genes (Suppl. Fig. 1), fold 
changes of transcripts were calculated to those of non-infected humanized livers from mice transplanted with the 
identical hepatocyte donor.
Cytokine measurement. Human CXCL10 was measured in 1:5 diluted mouse serum samples using the 
Human CXCL10/IP10 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA) according to manufac-
turer’s protocol.
Nanostring analyses. RNA was isolated from chimeric mouse livers as described above. The nCounter GX 
human Immunology V2 Kit (NanoString Technologies, Seattle, WA, USA) was used to measure the expression 
of 594 human genes in the RNA of these samples. Following hybridization, transcripts were quantitated using 
the nCounter Digital Analyzer. Samples were run at the Johns Hopkins Deep Sequencing & Microarray Core 
facility. To correct for background levels, the highest negative control value for each sample was subtracted from 
each count value of that sample, as described previously50, 51. Following background subtraction, any negative 
Virus Genotype Strain/Isolate* Source Inoculum
HEV 1 Sar-55 Rhesus macaque feces feces suspension
HEV 3 HEV0069* Chronic HEV patient feces feces suspension
HEV 3 HEV0122* Chronic HEV patient feces feces suspension
HBV A Chronic HBV patient serum serum
Table 2. Viral isolates.
Treatment Chimeric liver Virus n= Hepatocyte donor
None
no None 3 n/a*
yes None 8 HD1, HD2
yes HEV gt1 10 HD1
yes HEV gt3 (HEV0069) 16 HD1, HD2, HD3
yes HEV gt3 (HEV0122) 4 HD1
yes HBV gtA 5 HD3
pegIFNα-2a
no None 2 n/a*
yes None 2 HD2
yes HEV gt1 3 HD2
yes HEV gt3 (HEV0069) 11 HD2
yes HBV gtA 6 HD2
Table 3. Overview of experimental groups. *n/a, not applicable.
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count values were considered as 0. The geometric mean of 5 housekeeping genes provided by the company panel 
was calculated and used to normalize expression values. RNA from non-chimeric mouse livers was used as con-
trol to test cross-reactivity of genes. Fifty cross-reactive genes were removed prior to analyses of the data set. 
Non-expressed genes were defined as < 100 relative RNA counts and below four times the standard deviation in 
all samples.
Statistics. Differences between groups were calculated using two tailed Mann-Whitney test or Kruskal-Wallis 
one-way ANOVA with Dunn’s all column comparison post-test (GraphPad Prism version 5.01; GraphPad 
Software). Differences were considered significant when P < 0.05. Results are presented as the mean ± SEM. 
Principal component analyses was performed on log 2 transformed data set and heatmap of IFN signaling/
response genes was generated using Multi-experiment viewer (MeV) software version 4.9.
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